cyrilzakka/clinical-trials huggingface dataset:
The Effect of Motivational Interviewing on Problematic Internet Use and Loneliness

This research will examine the effect of online individual motivational interviewing applied to nursing students on problematic internet use and loneliness. Mixed method will be used in the research.

Problematic internet use is seen as a multidimensional syndrome consisting of cognitive and behavioral symptoms that cause negative social, academic and professional consequences. Problematic internet use to the individual; psychological effects such as eating disorder, depression, sleep disorder, addiction, anxiety, physical effects such as injury, posture disorders, social effects such as lack of social relations and loneliness. Many issues related to problematic internet use are mentioned. However, psychosocial intervention studies to help problematic internet use remain a subject of little research.

Eligibility Criteria:
Inclusion Criteria:

1. Being in the pre-intention or intention stage according to the motivational interview change cycle determination form,
2. Scoring above the problematic internet use scale average,
3. Volunteer to participate in the study,
4. Having no problems with speaking and understanding Turkish

Exclusion Criteria:

1. Having a psychiatric diagnosis
2. Receiving ongoing individual or group counseling
3. Being in the phase of preparation, action or maintenance from the change phases
4. Not wanting to continue research
Retrospective Evaluation of Safety and Efficacy of Daptomycin Used in Patients With Serious Gram-positive Infections

Daptomycin was approved since 2005 in Taiwan and have been studied and published in west countries. After review the published papers, the few data were described in the Asian countries or Taiwan. The objectives of this study are to evaluate the efficacy and safety of daptomycin for the treatment of Gram-positive infections under actual conditions of use, and to understand other information concerned with daptomycin prescription. This study represents an opportunity for acquiring real world data on daptomycin usage, and may provide physicians in Taiwan with the information of characteristic of the patients receiving daptomycin and to evaluate outcomes. It also provides a means to identify safety signals that emerge with clinical usage.

This is a retrospective, non-comparative study, which will be performed after obtaining permission from the institutional review board. Patients with serious gram-positive infections who had received daptomycin from January 2009 and completed daptomycin therapy by the end of December 2010 will be screened, and patients who received ≥ 3 days of daptomycin will be identified eligible to be included. Eligible patients' medical records will be reviewed.

As this is a retrospective chart review, it is expected that informed consent will not be necessary. For patients' confidentiality concern, patients' name or chart number will not to be record in any part of Data Collection Form (APPENDIX 1). A patient identification number will be assigned to each patient included in this surveillance. A study coordinator at site will be identified, and hospital specific process will be utilized to identify patients. Information to be collected was shown on Data Collection Form (Appendix 1). After completing patient data collection, the efficacy and safety will be evaluated for the included cases.

Eligibility Criteria:
Inclusion Criteria:

* Patients started daptomycin therapy since January 2009.
* Patients completed daptomycin therapy by the end of December 2010.
* Patients had Gram positive infections.
* Patients received daptomycin therapy for at least 3 days.

Exclusion Criteria:

* Daptomycin therapy will be chosen by the treating physician based on clinical indication and it is expected that risks of therapy will have already been considered.
* subjects are only to be excluded if he/she was enrolled in any antibiotics clinical trial during daptomycin treatment.
Radiation Therapy in Treating Patients With Stage II Cancer of the Vocal Cord

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective in treating patients with stage II cancer of the vocal cord.

PURPOSE: Randomized phase III trial to compare two regimens of radiation therapy in treating patients who have stage II cancer of the vocal cord.

OBJECTIVES:

* Compare the local response rate in patients with stage II invasive squamous cell carcinoma of the true vocal cord treated with hyperfractionation vs conventional fractionation radiotherapy.
* Compare the acute and late toxic effects of these regimens in this patient population.
* Compare the overall and disease-free survival patterns in this patient population treated with these regimens.

OUTLINE: This is a randomized study. Patients are stratified according to substage (T2a vs T2b). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients undergo conventional radiotherapy 5 days a week for 5 weeks followed by boost radiotherapy 5 days a week for 2 weeks.
* Arm II: Patients undergo hyperfractionation radiotherapy 5 days a week for 5 weeks followed by boost radiotherapy 5 days a week for 1.6 weeks.

Patients with biopsy-proven persistent disease at least 6 weeks after completion of radiotherapy undergo salvage surgery with neck dissection (at the discretion of the surgeon).

Patients are followed at 4 weeks, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 240 patients will be accrued for this study within 3.2 years.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Histologically proven invasive squamous cell carcinoma of the true vocal cord

  * Stage II (T2a/b N0) disease with bulk of tumor present on vocal cord (i.e., the epicenter) with extension to adjacent areas
* No verrucal carcinoma or adenocarcinoma
* No extension to pre-epiglottic space or pyriform sinus
* No fixed cord or cartilage invasion
* No evidence of adenopathy, including any of the following:

  * Nodes larger than 1 cm by radiography
  * Nodes containing a low central density consistent with necrosis by radiography
  * Clinically palpable nodes larger than 1 cm and firm in consistency
* No recurrent or persistent disease
* No evidence or suspicion of distant metastases

PATIENT CHARACTERISTICS:

Age:

* 18 and over

Performance status:

* Karnofsky 60-100%

Life expectancy:

* Not specified

Hematopoietic:

* Not specified

Hepatic:

* Not specified

Renal:

* Not specified

Other:

* No other malignancy within the past 5 years except nonmelanomatous skin cancer
* Not pregnant or nursing
* Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* Not specified

Chemotherapy:

* No prior chemotherapy

Endocrine therapy:

* Not specified

Radiotherapy:

* No prior radiotherapy to the mid-neck or larynx

Surgery:

* No prior complete stripping or laser excision of all gross disease
Coordination of Hemiparetic Movement After Post-Stroke Rehabilitation

This study will determine whether a therapeutic exercise program for improving motor coordination in locomotor tasks in post-stroke, hemiparesis patients will result in CNS recovery. The study will develop relationships between the improved motor performance and motor coordination during the locomotor task and the functional effects of the exercise program(e.g., gait variables.)

Primary objective of this study is to determine whether a therapeutic exercise program which targets the functional recovery of persons with the post-stroke hemiparesis results in CNS recovery (improved motor coordination). They will determine whether motor coordination during a locomotor task is improved after an exercise program. They will then develop relationships between the improved motor performance and motor coordination during the locomotor task and the functional effects of the exercise program(e.g., gait variables) Overall goal is to develop a more rational basis for the design of stroke rehabilitation programs which target individuals most likely to recover and which are based on physiological principles. This study will supplement an NIH funded randomized clinical trial to evaluate a post-stroke exercise program designed to increase balance, strength, and endurance. Study will include 60-70 prospective patients enrolled in the randomized clinical trial at Kansas University Center on Aging. between Oct 1999 and Oct 2001.

Eligibility Criteria:
Inclusion Criteria:

Functionally impaired elderly

Exclusion Criteria:
Register of Telaprevir and Boceprevir in Routine Clinical Practice

Know through routine clinical practice the effectiveness and safety of current treatment of hepatitis C virus, genotype 1, for patients who have never been treated and for patients who have been previously treated


Eligibility Criteria:
Inclusion Criteria:

* Patients infected by hepatitis C virus, genotype 1
* Indication of treatment with telaprevir or boceprevir in F3 and F4 fibrosis

Exclusion Criteria:

* Being taking part in other
* Inability to follow a monitoring
* Contra-indications on triple therapy
* Coinfected with HIV and HBV (hepatitis B virus)
Procalcitonin Role in Influenza Patients With Regard to Morbidity, Mortality and Antibiotic Use

The investigators intend to observe the inflammatory marker procalcitonin (PCT) in comparison with patient variables on morbidity, mortality and antibiotic treatment.

The overall aim is to observe if a low PCT value can have potential in reducing unessesary antibiotic use in seasonal influenza patients.

This is an observational study of the clinical utility of early PCT measurements in seasonal influenza, with particular attention to PCT's predictive value for prognosis and bacterial respiratory superinfection. The aim is to evaluate PCT as a supplementary aid in the standard clinical evaluation of influenza patients. Patients may be included if a positive influenza test is reported within 48 hours after an initial clinical suspicion of influenza, and the hospital stay is lasting more than one day. The investigators have included 74 patients from the second half of the 2018-19 influenza season and will continue to include patients from the complete 2019-20 season.

Primary endpoints: Mortality (in-hospital and within 30 days post-discharge), bacterial respiratory tract superinfection.

Secondary endpoints: Intensive care unit stay, the proportion of patients on antibiotic use and total antibiotic use in doses and LOT ("length-of-treatment").

Eligibility Criteria:
Inclusion Criteria:

* patient admitted to the hospital with positive influenza test

Exclusion Criteria:

* none
A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B

This is a prospective, multicentre observational study of Chronic Hepatitis B （CHB）in different clinical stages. We intend to compare the immune status of various types of CHB patients, and we propose to establish a staging and grading criteria for the immune exhaustion status of patients with CHB.

Two groups were included in this study: untreated patients who met the staging subgroups according to Chinese Guidelines for the Prevention and Control of Chronic Hepatitis B, 2022 edition or HBsAg negativity（Group 1). The another is those who achieved HBV DNA suppression by NA（Group 2）. Patients in Group 1 will be followed up once every six months, and in group 2 will be followed up once every three months. And patients treated or not treated will be followed up in the study. The treatment with NA or combined with interferon will be decided by the consensus of doctors and patients. This study does not intervene the treatment, but will register the clinical indicators. We follow up the patients at each follow-up time point, record the subjects' clinical indicators at each visit and obtained serum and PBMC specimens for further immune study after the consents of the patients.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with CHB who were older than 18 years old and younger than 50 years old with HBsAg positivity more than 6 months;
2. Group 1 untreated group fulfils any one of the four natural history types of the Chinese Guidelines for the Prevention and Control of Chronic Hepatitis B, 2022.
3. Group 2 nucleos(t)ide-treated CHB patients are required to have sustained control of their HBV DNA (\<100 IU/ml).

Exclusion Criteria:

1. Pregnancy status;
2. Has been diagnosed with compensated/lost compensated cirrhosis, hepatocellular carcinoma by imaging or other indicators;
3. Combined HAV, HCV, HEV infection, schistosomal liver disease, drug-induced liver injury, autoimmune hepatitis, alcoholic liver disease, severe fatty liver, HIV infection;
4. Being on immunosuppressants or immunomodulators or hormonal drugs or biological agents, etc;
5. previous history of oncology, organ transplantation, etc., history of alcoholism (\>30 g/d for men, \>20 g/d for women);
6. Inadequate follow-up time and inadequate clinical/laboratory information;
7. Combined heart, brain, kidney, lung and other organ insufficiency or combined endocrine and haematological system and other major diseases;
8. Comorbid serious psychiatric diseases including severe anxiety or depression;
9. Unwilling to participate in this study.
Temporomandibular Joint and Soft Tissue Mobilisation Techniques on Bening Paroxymal Vertigo

The purpose of this study was to investigated effectiveness of temporamandibular joint and soft tissue mobilization on patients with Benign Paroxysmal Positional Vertigo (BPPV).

Aim: In this study was aimed to investigated effectiveness of temporamandibular joint and soft tissue mobilization on patients with Benign Paroxysmal Positional Vertigo (BPPV). Material and Methods; Dix Hallpike maneuver was administered to all patients to confirm the diagnosis at the initial evaluation. If the Dix Hallpike test was positive, Epley maneuver was applied The patients were randomly divided into 2 groups as study group (n=) and control groups (n= ). Temporomandibular joint ve soft tissue techniques were applied 30 minutes once a week for 4 weeks by physiotherapist. Routin medication therapy was applied to control group. Both groups were asked to do the home exercise program twice a day consisting of vestibular exercise videos sent over whatss app. It was questioned with a phone call once a week whether the exercises were done or not. Patients were evaluated by Dizziness Disability Inventory (DHI) , Dizziness Assessment- Visual Analogue Scale (VAS), Vertigo Symptom Scale-Short Form (VSS) , Beck Anxiety Inventory (BAI) , Vertigo Dizziness Imbalance Questionnaire (VDI) , Tinnitus Disability Scale (TDS), Romberg Posture Test , Tandem Posture Test, Semitandem Tandem Balance Test, Fonseca's Anamnestic Index (FAI) and amount of mouth opening was measured with goniometer before and after treatment.

Eligibility Criteria:
Inclusion Criteria:

* Being diagnosed with positional vertigo,
* Being between the ages of 18-65
* Dix Halpike maneuver test (+),
* Those who volunteered to participate in the study
* Able to read and write.

Exclusion Criteria:

* Findings of acute or chronic infection at the end of ENT examination,
* Considered to have a neurological pathology that causes dizziness,
* Head trauma, history of surgical operation,
* Having lower extremity pain that prevents standing and weight bearing,
* Having a history or symptoms of vestibular system diseases other than BPPV,
* Presence of sudden sensory hearing loss and chronic otitis media,
* Pregnancy,
* The presence of serious cognitive impairment detected by the physician at a level that prevents the tests from being performed,
* Not having the mental level to understand and answer the survey questions,
* Cervical pathologies that may cause dizziness.
Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

To evaluate the safety and efficacy of two dose ranges of safinamide (High Dose: 150 to 200 mg/day and Low Dose: 50 to 100 mg/day) orally, as compared to Placebo, as add-on therapy in patients with early idiopathic Parkinson's disease who are currently receiving a stable dose of a single dopamine agonist. It is hypothesized that, over a 24-week period, add-on treatment with safinamide will result in greater improvement of motor symptoms in these patients, compared to treatment with a dopamine agonist alone.


Eligibility Criteria:
Inclusion Criteria:

* Patients with a diagnosis of idiopathic Parkinson's disease of less than 5 years duration, and a Hoehn and Yahr Stage of I to III,
* who were receiving treatment with a single dopamine agonist at a stable dose for at least 4 weeks prior to Visit 1 (Screening).

Exclusion Criteria:

* Patients with medical conditions and/or taking concomitant medications that would have put them at risk, interfered with the study evaluations, or made them unable to complete the requirements of the study;
* patients with a diagnosis or recent history of substance abuse,
* a history of psychosis,
* who were depressed,
* had evidence of dementia or cognitive dysfunction,
* or who were experiencing end of dose wearing-off;
* female patients of childbearing potential;
* patients who have previously received safinamide.
Using Models' Facial Expressions to Enhance Healthy Eating Behaviour in Children

This study examined the effect of adults' facial expressions (FEs) whilst eating raw broccoli on children's acceptance and intake of a typically less preferred vegetable. Investigating others' FEs in isolation (e.g., without statements about food tastiness) will improve understanding of the role of FEs in modelling of eating and contribute to developing strategies to help children learn pleasure from nutritious foods. Based on previous literature, it was hypothesised that children's acceptance (willingness to try, and frequency of taste exposures) and intake of raw broccoli would be higher after exposure to models eating raw broccoli with positive FEs, compared to models consuming raw broccoli with neutral FEs, or a non-food control video.

Research has shown that seeing positive facial expressions towards food are effective for increasing children's desire to eat foods rated as disliked. However, the effect of adults' positive facial expressions whilst eating a raw vegetable on children's acceptance and consumption of nutritious foods that are less preferred (e.g., vegetables) remains to be established. This study examined the effect of unfamiliar adult models' facial expressions eating raw broccoli on children's acceptance and consumption of raw broccoli. Children aged 4-6-year-olds were randomised to watch a video of unfamiliar adult models eating raw broccoli with a positive or neutral facial expression, or a non-food control video. Children's acceptance (willingness to try and frequency of taste exposures) and consumption of raw broccoli was assessed. Data about parent and child characteristics was provided by parents.

Eligibility Criteria:
Inclusion Criteria:

* Child must be aged 4-6-years old. Parent and child must be living in the UK.

Exclusion Criteria:

* Children with food allergies, food intolerances, or medical conditions that affect eating behaviour were not eligible to take part.
Body Composition Measurements in Pneumonia

The purpose of this study is to validate and standardize bioelectrical impedance analysis (BIA, Maltron BioScan touch i8) for estimating body composition in hospitalized elderly patients with pneumonia. Body composition assessments with BIA and dual-energy x-ray absorptiometry (DXA,

Holigic Discovery) was performed on 36 non-fasting patients over 65 years of age. 29 patients had BIA performed within 24 hours after hospital admission and at the date of discharge. 17 patients had BIA performed in fasted state and one hour after an intake of 300 ml glucose solution.

Eligibility Criteria:
Inclusion Criteria:

* Acute pneumonia,
* Accept participation (informed consent)
* Understand the given instructions and information

Exclusion Criteria:

* None
MyHealtheVet to Enable Shared Decision Making Regarding Menopausal in Postmenopausal Women Veterans (MEANS)

The purpose of this research study is to examine the impact of educational secure messages on menopause. In particular, the investigators will examine whether the secure messages increase menopause knowledge and communication between patients and their providers.

The overall goal of this project is to determine the effectiveness of the MEANS (MyHealtheVet to Enable And Negotiate for Shared decision making) intervention in improving women's self-reported knowledge and rates of diagnosis and appropriate management of menopause symptoms. The proposed intervention is an educational and shared decision making platform for menopause symptoms to improve communication between patients and their providers regarding menopause symptoms. MEANS combines educational secure messages through the Veterans Affairs online Personal Health Record called MyHealtheVet, along with face-to-face and print interventions.

MEANS will be applied in target population consisting of postmenopausal women Veterans ages 45 to 60 who receive primary care at the Miami Veterans Affairs Healthcare System. This project will enroll women in MyHealtheVet, develop a library of menopause symptoms material for distribution, and evaluate how useful of MyHealtheVet use for educating and tracking women regarding menopause symptoms.

Eligibility Criteria:
Inclusion Criteria:

* Women Veterans, age 45-60
* Receive primary care at the Miami Veterans Affairs Healthcare System
* Able to communicate in English
* Already or willing to register and become authenticated in the patient health portal, MyHealtheVet.
* Able to use read, understand, and respond to secure messages using patient health portal.

Exclusion Criteria:

* Not willing to register and become authenticated for patient health portal.
* Not willing to receive educational secure messages from patient health portal.
Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fasted Conditions

The objective of this study was to prove the bioequivalence of Mycophenolate Mofetil 500 mg tablets under fasted conditions.


Eligibility Criteria:
Inclusion Criteria:

* No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

* Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to mycophenolate mofetil or any comparable or similar product.